Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sectra ABCHIX:SECTBS 98 Debt-to-EBITDA is 0.08 as of Apr. 2026, which is 38% below its 10-year median of 0.13. GuruFocus rates CHIX:SECTBS with a GF Score™ of 98/100 and a GF Value™ of kr309.99 (Modestly Undervalued). Among 470 Medical Devices & Instruments companies, Sectra AB ranks better than 91.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sectra AB's Debt-to-EBITDA or its related term are showing as below:
CHIX:SECTBs'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.05 Med: 0.13 Max: 0.23
Current: 0.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sectra AB was 0.23. The lowest was 0.05. And the median was 0.13.
CHIX:SECTBs's Debt-to-EBITDA is ranked better than 91.06% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs CHIX:SECTBs: 0.09
Sectra AB (CHIX:SECTBs) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sectra AB Debt-to-EBITDA Related Terms
Sectra AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sectra AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SECTBS vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Sectra AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sectra AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sectra AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sectra AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Sectra AB (CHIX:SECTBS) has a Debt-to-EBITDA of 0.08 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sectra AB. This is 38% below median its historical median of 0.13. Over the past decade, Sectra AB's Debt-to-EBITDA has ranged from 0.05 to 0.23. According to the industry distribution chart, Sectra AB ranks #42 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Sectra AB's Debt-to-EBITDA too high?
Sectra AB's current Debt-to-EBITDA of 0.08 is 38% below median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.23. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Sectra AB's value of 0.08 is 95% below this industry median. Based on the distribution chart, Sectra AB ranks #42 out of 470 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sectra AB has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sectra AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sectra AB ranks #42 out of 470 companies for Debt-to-EBITDA. This places Sectra AB in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.59. Sectra AB's value of 0.08 is 95% below this benchmark. Historically, Sectra AB's own Debt-to-EBITDA has ranged from 0.05 to 0.23 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 1.59, Sectra AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sectra AB's current Debt-to-EBITDA of 0.08 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sectra AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sectra AB's current Debt-to-EBITDA is 0.08, which is 38% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sectra AB stock overvalued right now?
Based on GuruFocus' analysis, Sectra AB (CHIX:SECTBS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr309.99, compared to a current price of kr277.30 — trading 10.5% below its estimated fair value. The current Debt-to-EBITDA is 0.08, which is 38% below median its 10-year median of 0.13 and 95% below the Medical Devices & Instruments industry median of 1.59. Sectra AB's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sectra AB (CHIX:SECTBS), the current Debt-to-EBITDA is 0.08 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sectra AB (CHIX:SECTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Sectra AB stock appears to be undervalued.
The current stock price of kr277.30 is trading 10.5% below its estimated GF Value™ of kr309.99.
GuruFocus considers Sectra AB to be Modestly Undervalued.
Key valuation signals for CHIX:SECTBS:
Debt-to-EBITDA: 0.08 (38% below median its 10-year median of 0.13)
GF Value™: kr309.99 vs. price of kr277.30 (10.5% below fair value)
Industry Position: 95% below the Medical Devices & Instruments median (#42 of 470)
No single metric tells the full story. See the CHIX:SECTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sectra AB develops IT solutions and services for storing, viewing, and working with medical images. The operating business segments are Imaging IT Solutions, Secure Communications, Business Innovation, and Other Operations. It generates maximum revenue from the Imaging IT Solutions segment. The company also offers maintenance in the form of support, system monitoring, and consulting services related to integration, system design, data migration, and business development. Geographically, it derives a majority of its revenue from the United States, followed by Sweden, the United Kingdom, the Netherlands, the Rest of Europe, and the Rest of the world.
98GF Score
Get the complete analysis for CHIX:SECTBS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SECTBS has been successfully added to your 
